pharma news today glp-1 obesity drugs A harsh market reality: weight-loss efficacy means less if patients can't stay on the drug. CNBC reports Zealand stock suffered its two worst days on record after trial data on GLP-1 agonists and changes in

Feel free to bring anything that will help you relax, though, including earbuds or the book youre reading

The transition from animal wound healing to human wound healing applications has not been systematically pursued in clinical trials, despite the preclinical evidence

Feeling better at week two does not mean the tendon can safely handle maximum-effort loading

Furthermore, there was an increased risk of serious adverse events including an increased incidence of disturbances in diabetes control and diabetes diagnoses, as well as serious gastrointestinal, musculoskeletal, dermatological, infectious, and bleeding adverse events

-blockers and other antihypertensives present endocrine-disrupting potential and may impact aquatic microbial and algal populations [72]